신속 혈장 반응 검사(RPR) 시장 규모, 점유율, 성장 분석 : 검체별, 검사 유형별, 용도별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Rapid Plasma Reagin Test Market size was valued at USD 3.09 Billion in 2024 and is poised to grow from USD 3.41 Billion in 2025 to USD 7.46 Billion by 2033, growing at a CAGR of 10.3% during the forecast period (2026-2033).

The increasing incidence of syphilis, particularly among high-risk populations like men who have sex with men and pregnant women, significantly boosts the demand for rapid plasma reagin tests. Innovations in testing technologies, such as automated systems, enhance efficiency in high-volume laboratories by streamlining sample processing and reducing errors. Government initiatives focused on STI prevention further support market growth, alongside a strong preference for point-of-care testing, which offers quick results. Additionally, rising awareness in developing countries about syphilis and STIs is expected to drive sales. However, challenges remain, including limited access in low-resource environments, competition from alternative diagnostic methods, issues with false positives, and regulatory hurdles that may hinder market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rapid Plasma Reagin Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rapid Plasma Reagin Test Market Segments Analysis

Global Rapid Plasma Reagin Test Market is segmented by Specimen, Test Type, Application, End User and region. Based on Specimen, the market is segmented into Blood, Serum and Plasma. Based on Test Type, the market is segmented into Traditional Tests and Rapid Tests. Based on Application, the market is segmented into Diagnostics and Screening. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rapid Plasma Reagin Test Market

The growing prevalence of chronic illnesses, along with heightened awareness around health and wellness, is driving a significant rise in the demand for preventive healthcare solutions. Routine screening for syphilis, facilitated by the Rapid Plasma Reagin (RPR) test, plays a critical role in early detection, preventing complications, and limiting the infection's spread. Healthcare providers are increasingly incorporating RPR testing into standard preventive care practices, particularly for populations at higher risk. This initiative supports overarching public health objectives aimed at lowering the incidence of sexually transmitted infections and encourages consistent screening among at-risk individuals, reinforcing the importance of proactive health management.

Restraints in the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin Test market faces limitations due to biological factors like autoimmune disorders and various infections, which may result in non-specific responses and inaccurate test outcomes. This necessitates additional confirmatory testing, consequently extending the time required for accurate diagnosis and treatment. Such challenges can undermine the perceived reliability of rapid plasma reagin tests among healthcare professionals, potentially steering them towards alternative diagnostic options. As a result, these issues may hinder the widespread acceptance and continuous utilization of rapid plasma reagin tests, ultimately impacting the growth and evolution of the market in the future.

Market Trends of the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin (RPR) Test market is witnessing a significant trend towards the integration of RPR testing with multiplex diagnostic platforms. This innovation enhances efficiency in sexually transmitted infection (STI) screening by allowing the simultaneous detection of multiple infections, such as HIV, syphilis, and hepatitis, from a single sample. The resulting reduction in testing time, costs, and logistical complexities makes this approach particularly beneficial in resource-limited settings. By embedding RPR into comprehensive testing strategies, healthcare providers can improve diagnostic coverage and adopt a holistic approach to STI management, driving the broader acceptance and utilization of RPR tests across the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Rapid Plasma Reagin Test Market Size by Specimen & CAGR (2026-2033)

• Market Overview
• Blood
• Serum
• Plasma

Global Rapid Plasma Reagin Test Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Traditional Tests
• Rapid Tests

Global Rapid Plasma Reagin Test Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diagnostics
• Screening

Global Rapid Plasma Reagin Test Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes

Global Rapid Plasma Reagin Test Market Size & CAGR (2026-2033)

• North America (Specimen, Test Type, Application, End User)
  • US
  • Canada
• Europe (Specimen, Test Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Specimen, Test Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Specimen, Test Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Specimen, Test Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sekisui Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meridian Bioscience, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arlington Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunostics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novacyt Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trinity Biotech plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atlas Medical GmbH (Germany/UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sclavo Diagnostics International S.r.l. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations